What is Leerink Partnrs’ Forecast for AXSM FY2027 Earnings?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Investment analysts at Leerink Partnrs lifted their FY2027 earnings per share (EPS) estimates for shares of Axsome Therapeutics in a report released on Sunday, April 13th. Leerink Partnrs analyst M. Goodman now forecasts that the company will earn $4.20 per share for the year, up from their previous forecast of $4.10. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share.

Axsome Therapeutics (NASDAQ:AXSM) last released its earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The company had revenue of $118.77 million for the quarter, compared to analysts’ expectations of $117.83 million.

A number of other research analysts have also recently weighed in on the company. Leerink Partners raised their price target on Axsome Therapeutics from $110.00 to $150.00 and gave the company an “outperform” rating in a research report on Monday, February 10th. Needham & Company LLC restated a “buy” rating and set a $153.00 target price on shares of Axsome Therapeutics in a research report on Tuesday, April 1st. Deutsche Bank Aktiengesellschaft began coverage on shares of Axsome Therapeutics in a report on Tuesday, February 11th. They issued a “buy” rating and a $176.00 price target on the stock. William Blair reissued an “outperform” rating on shares of Axsome Therapeutics in a research note on Tuesday, February 18th. Finally, Truist Financial upped their target price on Axsome Therapeutics from $190.00 to $200.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $169.80.

Axsome Therapeutics Trading Up 0.3 %

Shares of AXSM opened at $103.83 on Tuesday. Axsome Therapeutics has a twelve month low of $64.11 and a twelve month high of $139.13. The company has a current ratio of 2.11, a quick ratio of 2.04 and a debt-to-equity ratio of 3.22. The firm has a market capitalization of $5.06 billion, a P/E ratio of -17.33 and a beta of 0.88. The firm’s 50-day moving average is $119.19 and its two-hundred day moving average is $102.18.

Institutional Trading of Axsome Therapeutics

A number of hedge funds have recently made changes to their positions in AXSM. JPMorgan Chase & Co. increased its position in Axsome Therapeutics by 14.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company’s stock worth $19,062,000 after purchasing an additional 27,534 shares during the last quarter. Strategic Financial Concepts LLC bought a new stake in shares of Axsome Therapeutics during the 4th quarter worth about $2,599,000. Intech Investment Management LLC raised its stake in shares of Axsome Therapeutics by 46.5% in the 4th quarter. Intech Investment Management LLC now owns 16,028 shares of the company’s stock valued at $1,356,000 after acquiring an additional 5,087 shares in the last quarter. Raymond James Financial Inc. bought a new stake in Axsome Therapeutics during the fourth quarter worth approximately $14,771,000. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Axsome Therapeutics by 1.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 328,034 shares of the company’s stock valued at $27,755,000 after purchasing an additional 5,438 shares during the period. 81.49% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CFO Nick Pizzie sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $131.07, for a total transaction of $393,210.00. Following the sale, the chief financial officer now owns 42,187 shares in the company, valued at $5,529,450.09. The trade was a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 22.40% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.